Trial Profile
A double-blind, placebo-controlled, pharmacokinetics, safety, and tolerability study to evaluate the single 500-mg or 1000-mg intravenous dose of dalbavancin in healthy japanese subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 Oct 2015
Price :
$35
*
At a glance
- Drugs Dalbavancin (Primary)
- Indications Bacterial infections
- Focus Pharmacokinetics; Therapeutic Use
- 21 Oct 2015 New trial record
- 12 Oct 2015 Results published in Clinical Drug Investigation